Q-omics provides the consensus-scored FAAH2 profile across patient tissues and cancer cell-line models. FAAH2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAAH2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, FAAH2 RNA expression shows 18,845 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where FAAH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAAH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAAH2 survival associations across molecular data types. FAAH2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAAH2 RNA expression–survival associations across cancer types. High FAAH2 expression shows unfavorable associations in ESCA, but favorable associations in KIRC, MESO, BLCA, SKCM and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAAH2 RNA expression.
This table summarizes FAAH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAAH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAAH2 shows lower tumor expression in KIRC and HNSC and higher tumor expression in COAD, THCA, BRCA and STAD. The COAD box plot shows higher FAAH2 RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with FAAH2 in patient tissues and cancer cell lines. In patient samples, FAAH2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, FAAH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LUNG_SCLC.
